RT Journal Article SR Electronic T1 High-dose vitamin D3 in the treatment of complicated severe acute malnutrition in Pakistan: a double-blind randomised controlled trial (ViDiSAM) JF medRxiv FD Cold Spring Harbor Laboratory Press SP 2024.07.20.24310735 DO 10.1101/2024.07.20.24310735 A1 Saleem, Javeria A1 Zakar, Rubeena A1 Butt, Muhammad Salman A1 Kaleem, Rameeza A1 Chaudhary, Asif A1 Chandna, Jaya A1 Jolliffe, David A A1 Piper, Joseph A1 Abbas, Zaigham A1 Tang, Jonathan C Y A1 Fraser, William D A1 Freemantle, Nick A1 Prendergast, Andrew J A1 Martineau, Adrian R YR 2024 UL http://medrxiv.org/content/early/2024/07/21/2024.07.20.24310735.abstract AB We have previously shown that high-dose vitamin D3 improved weight gain and neurodevelopmental indices in children receiving standard therapy for uncomplicated severe acute malnutrition (SAM). We conducted a randomised placebo-controlled trial to determine whether two oral doses of 200,000 international units (IU) vitamin D3 would benefit children aged 6-59 months receiving standard therapy for complicated SAM in Lahore, Pakistan. The primary outcome was mean weight-for-height or -length z-score (WHZ) at 2-month follow-up. Secondary efficacy outcomes were mean WHZ at 6-month follow-up and mean lean mass index, Malawi Development Assessment Tool (MDAT) scores and serum 25-hydroxyvitamin D (25[OH]D) concentrations at 2- and 6-month follow-up. 259 children were randomised (128 to vitamin D, 131 to placebo), of whom 251 (96.9%) contributed data to analysis of the primary outcome. At 2-month follow-up, participants allocated to vitamin D had significantly higher mean serum 25(OH)D concentrations than those allocated to placebo (adjusted mean difference [aMD] 100.0 nmol/L, 95% confidence interval [CI] 72.2 to 127.8 nmol/L). This was not associated with an inter-arm difference in mean WHZ (aMD 0.02, 95% CI -0.20 to 0.23), or in any other anthropometric or neurodevelopmental outcome assessed at 2- or 6-month follow-up overall. However, sub-group analyses revealed some evidence of greater benefit from the intervention among participants with baseline serum 25(OH)D concentrations <50 nmol/L vs. ≥50 nmol/L for the outcomes of mean WHZ at 2-month follow-up (P for interaction 0.13) and mean MDAT score at 2-month follow-up (P for interaction 0.039). The intervention was safe. In conclusion, high-dose vitamin D3 elevated mean serum 25(OH)D concentrations in children receiving standard therapy for complicated SAM in Pakistan, but did not influence any anthropometric or neurodevelopmental outcome studied overall. Further trials are needed to determine whether children with lower baseline vitamin D status benefit from this intervention. The trial was registered at ClinicalTrials.gov with the identifier NCT04270643.Competing Interest StatementARM declares receipt of funding in the last 36 months to support vitamin D research from the following companies who manufacture or sell vitamin D supplements: Pharma Nord Ltd, DSM Nutritional Products Ltd, Thornton & Ross Ltd and Hyphens Pharma Ltd. ARM also declares receipt of vitamin D capsules for clinical trial use from Pharma Nord Ltd, Synergy Biologics Ltd and Cytoplan Ltd; support for attending meetings from Pharma Nord Ltd and Abiogen Pharma Ltd; receipt of consultancy fees from DSM Nutritional Products Ltd and Qiagen Ltd; receipt of a speaker fee from the Linus Pauling Institute; participation on Data and Safety Monitoring Boards for the VITALITY trial (Vitamin D for Adolescents with HIV to reduce musculoskeletal morbidity and immunopathology, Pan African Clinical Trials Registry ref PACTR20200989766029) and the Trial of Vitamin D and Zinc Supplementation for Improving Treatment Outcomes Among COVID-19 Patients in India (ClinicalTrials.gov ref NCT04641195); and unpaid work as a Programme Committee member for the Vitamin D Workshop. All other authors declare that they have no competing interests.Clinical TrialNCT04270643Funding StatementThe trial was funded by the Thrasher Research Fund (ref 15080).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The trial was approved by the National Bioethics Committee (NBC) of Pakistan (ref. 4-87/NBC-516/20/477) and the Liverpool School of Tropical Medicine Research Ethics Committee (ref. 20-028).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAnonymised data are available from corresponding authors, subject to terms of IRB and regulatory approval.